Rehmann Capital Advisory Group’s Neurocrine Biosciences NBIX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-534	Closed	-$45.1K	–	1975
2019 Q2	$45.1K	Sell	534 -4	-0.7%	-$328	0.01%	872
2019 Q1	$47.4K	Sell	538 -10	-2%	-$836	0.01%	827
2018 Q4	$39.1K	Sell	548 -9	-2%	-$862	0.01%	666
2018 Q3	$68.5K	Buy	557 +197	+55%	+$22.4K	0.01%	695
2018 Q2	$35.4K	Buy	360 +14	+4%	+$1.25K	0.01%	903
2018 Q1	$29K	Buy	+346	New	+$29.2K	﹤0.01%	956

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rehmann Capital Advisory Group's NBIX Position: Q3 2019 in Review

Rehmann Capital Advisory Group sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 534 shares — an estimated $45.1K sold.

Rehmann Capital Advisory Group first reported a position in NBIX in Q1 2018 and held it in 6 quarters. The position peaked at $68.5K in Q3 2018. 332 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

Rehmann Capital Advisory Group reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
Rehmann Capital Advisory Group sold 534 Neurocrine Biosciences shares in Q3 2019, an estimated $45.1K.
Rehmann Capital Advisory Group first reported a position in Neurocrine Biosciences in Q1 2018 and held it in 6 quarters.
Rehmann Capital Advisory Group's Neurocrine Biosciences position peaked at $68.5K in Q3 2018.
332 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.